Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 50NIH 11INDUSTRY 3NETWORK 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

Paclitaxel 337pembrolizumab 333Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 240Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 170Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 119Prednisone 118Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Doxorubicin 98Leucovorin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 78Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Alemtuzumab × Clear all
NCT00206726 2016-08-29

ECO-1

Sanofi

Phase 2 Completed
60 enrolled 15 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00086580 2014-03-13

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

Sanofi

Phase 3 Completed
335 enrolled 43 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00328198 2014-03-13

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Sanofi

Phase 2 Completed
86 enrolled 15 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡